Citadel Advisors’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-238,912
| Closed | -$621K | – | 14057 |
|
|
2025
Q4 | $621K | Sell |
238,912
-460,385
| -66% | -$927K | ﹤0.01% | 8506 |
|
|
2025
Q3 | $1.23M | Sell |
699,297
-238,191
| -25% | -$381K | ﹤0.01% | 7095 |
|
|
2025
Q2 | $1.3M | Hold |
937,488
| – | – | ﹤0.01% | 6530 |
|
|
2025
Q1 | $924K | Buy |
+937,488
| New | +$1.13M | ﹤0.01% | 7144 |
|
|
2024
Q4 | – | Sell |
-102,860
| Closed | -$354K | – | 15251 |
|
|
2024
Q3 | $354K | Sell |
102,860
-37,501
| -27% | -$123K | ﹤0.01% | 8969 |
|
|
2024
Q2 | $463K | Buy |
140,361
+73,790
| +111% | +$263K | ﹤0.01% | 8205 |
|
|
2024
Q1 | $314K | Buy |
66,571
+19,945
| +43% | +$128K | ﹤0.01% | 9364 |
|
|
2023
Q4 | $340K | Sell |
46,626
-72,239
| -61% | -$404K | ﹤0.01% | 8913 |
|
|
2023
Q3 | $1.44M | Sell |
118,865
-95,763
| -45% | -$988K | ﹤0.01% | 5856 |
|
|
2023
Q2 | $2.27M | Buy |
214,628
+204,970
| +2,122% | +$2.11M | ﹤0.01% | 4940 |
|
|
2023
Q1 | $95K | Sell |
9,658
-182,820
| -95% | -$2.1M | ﹤0.01% | 11340 |
|
|
2022
Q4 | $2.83M | Sell |
192,478
-120,798
| -39% | -$1.81M | ﹤0.01% | 4848 |
|
|
2022
Q3 | $3.8M | Buy |
313,276
+172,256
| +122% | +$2.22M | ﹤0.01% | 4349 |
|
|
2022
Q2 | $1.97M | Buy |
141,020
+82,093
| +139% | +$967K | ﹤0.01% | 5575 |
|
|
2022
Q1 | $839K | Sell |
58,927
-5,686
| -9% | -$84.3K | ﹤0.01% | 8113 |
|
|
2021
Q4 | $1.36M | Sell |
64,613
-1,436
| -2% | -$33.8K | ﹤0.01% | 7121 |
|
|
2021
Q3 | $1.73M | Sell |
66,049
-150,651
| -70% | -$4.87M | ﹤0.01% | 6729 |
|
|
2021
Q2 | $6.76M | Buy |
216,700
+184,378
| +570% | +$6.04M | ﹤0.01% | 3816 |
|
|
2021
Q1 | $992K | Buy |
32,322
+20,770
| +180% | +$706K | ﹤0.01% | 8123 |
|
|
2020
Q4 | $396K | Buy |
11,552
+3,646
| +46% | +$109K | ﹤0.01% | 8588 |
|
|
2020
Q3 | $243K | Sell |
7,906
-14,659
| -65% | -$388K | ﹤0.01% | 8492 |
|
|
2020
Q2 | $700K | Buy |
+22,565
| New | +$724K | ﹤0.01% | 6473 |
|
Citadel Advisors's RPTX Position: Q1 2026 in Review
Citadel Advisors sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 238,912 shares — an estimated $621K sold.
Citadel Advisors first reported a position in RPTX in Q2 2020 and held it in 22 quarters. The position peaked at $6.76M in Q2 2021. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Citadel Advisors reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 238,912 Repare Therapeutics shares in Q1 2026, an estimated $621K.
- Citadel Advisors first reported a position in Repare Therapeutics in Q2 2020 and held it in 22 quarters.
- Citadel Advisors's Repare Therapeutics position peaked at $6.76M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.